Posted On July 25, 2014
Miracor has developed and is commercializing the Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO®) technology for heart attack patients. The devices are CE-marked and the company is conducting post clearance clinical trials in acute coronary syndrome patients. PICSO® holds the promise to improve outcomes for patients undergoing coronary revascularization and also holds promise for heart failure patients.
Leave a Reply